Table 3. Pooled ORR in breast cancer patients.

Study	Overall				PD-L1 positive
	n	MR	95% CI		n	MR	95% CI
TNBC/anti-PD-L1 + nab-paclitaxel
IMpassion130	450	0.560	0.514–0.606		185	0.589	0.518–0.660
GP28328	33	0.394	0.227–0.561		12	0.417	0.138–0.696
Sub-total	483	0.497	0.339–0.655		197	0.558	0.429–0.688
TNBC + non-TNBC/Anti-PD-L1
JAVELIN	168	0.030	0.004–0.056		85	0.024	−0.009–0.057
TNBC/anti-PD-L1
PCD4989g	115	0.096	0.042–0.150		91	0.121	0.054–0.188
TNBC/anti-PD-1
KEYNOTE-012	27	0.185	0.039–0.331		27	0.185	0.039–0.331
KEYNOTE-086 cohort A	170	0.053	0.019–0.087		105	0.057	0.013–0.101
KEYNOTE-086 cohort B	84	0.214	0.126–0.302		84	0.214	0.126–0.302
Sub-total	281	0.142	0.018–0.266		216	0.144	0.025–0.263
Non-TNBC/Anti-PD-1 + trastuzumab
PANACEA	58	0.121	0.037–0.205		46	0.152	0.048–0.256
Non-TNBC/anti-PD-1
KEYNOTE-028	25	0.120	−0.007–0.247		25	0.120	−0.007–0.247

ORR, objective response rate; TNBC, triple-negative breast cancer; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; n, number of patients; MR, mean rate; CI, confidence interval.